ITCI

Intra-Cellular Therapies Inc

ITCI.US intracellulartherapies.com + Research + Basket
CIK 0001567514
Employees 860
Phone 646 440 9333
Fiscal year end December
IPO Jan 07, 2014
Address 135 Route 202/206, Bedminster, NJ, United States, 07921
Price N/A
USD · NASDAQ
52-week range
0.00
0.00
Market Cap
14.05B
P/E Ratio
0.00
Forward P/E
158.73
Book Value
10.81
Div. Yield
N/A
% Institutions
96.45%
% Insiders
2.48%

1 Year

+93.2%

3 Year

+109.0%

10 Year

+462.8%
Description

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.

Actions

Add an action for ITCI.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Sharon Mates Ph.D. Co-Founder, Chairman & CEO 1953
Mr. Michael I. Halstead J.D. President 1973
Mr. Sanjeev Narula Executive VP, CFO & Treasurer 1962
Dr. Suresh K. Durgam M.D. Executive VP & Chief Medical Officer 1970
Mr. Mark Neumann EVP & Chief Commercial Officer 1964
Dr. Robert E. Davis Ph.D. Senior VP & Chief Scientific Officer 1951
Mr. Juan Fernando Sanchez M.D. Vice President of Corporate Communications & Investor Relations 1971
Ms. Karen Patruno Sheehy Esq. Senior VP & Chief Compliance Officer 1962
John P. Condon Senior VP, General Counsel & Secretary NA
Dr. Michael Olchaskey Pharm.D. Senior VP & Head of Regulatory Affairs NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 03, 2025 Josh Gottheimer N/A Sale N/A $131.87 N/A —
Apr 03, 2025 Gilbert Ray Cisneros, Jr. N/A Sale N/A $131.87 N/A —
Mar 24, 2025 Gilbert Ray Cisneros, Jr. N/A Sale N/A $131.70 N/A —
Mar 17, 2025 Josh Gottheimer N/A Sale N/A $131.45 N/A —
Jan 24, 2025 Josh Gottheimer N/A Sale N/A $127.35 N/A —
Dec 04, 2024 Sharon Mates N/A Sale 51.00K $85.80 $4.38M SEC
Nov 12, 2024 Michael Halstead N/A Sale 22.87K $89.12 $2.04M SEC
Aug 30, 2024 Sharon Mates N/A Sale 34.40K $72.84 $2.51M SEC
Aug 27, 2024 Sharon Mates N/A Sale 40.51K $73.58 $2.98M SEC
Aug 23, 2024 Sharon Mates N/A Sale 28.68K $74.46 $2.14M SEC
Aug 21, 2024 Sharon Mates N/A Sale 53.01K $75.65 $4.01M SEC
Aug 16, 2024 Mark Neumann N/A Sale 18.71K $75.08 $1.41M SEC
Jun 24, 2024 Rory B Riggs N/A Sale 4.46K $75.57 $337.19K SEC
Jun 21, 2024 Josh Gottheimer N/A Sale N/A $76.58 N/A —
Jun 18, 2024 Nostrand Robert L Van N/A Sale 20.00K $75.91 $1.52M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 9.52M Mar 31, 2025 8.95% $0.02 -2.07%
BlackRock Inc 8.75M Mar 31, 2025 8.23% $0.02 43.23%
Pentwater Capital Management LP 5.19M Mar 31, 2025 4.88% $5.75 0.00%
Davidson Kempner Capital Management LP 3.49M Mar 31, 2025 3.28% $9.46 0.00%
NORGES BANK 3.21M Dec 31, 2024 3.02% $0.04 65.30%
UBS O'Connor LLC 3.09M Mar 31, 2025 2.91% $33.23 15,139.27%
Amvescap Plc. 3.08M Dec 31, 2024 2.89% $0.05 2.93%
Farallon Capital Management, L.L.C. 3.06M Mar 31, 2025 2.87% $2.25 0.00%
FMR Inc 2.66M Mar 31, 2025 2.50% $0.02 -75.96%
Balyasny Asset Management LLC 2.26M Mar 31, 2025 2.12% $0.49 1,516.72%
Deep Track Capital, LP 2.00M Mar 31, 2025 1.88% $8.54 0.00%
Geode Capital Management, LLC 1.83M Mar 31, 2025 1.72% $0.02 6.71%
Bank of America Corp 1.82M Mar 31, 2025 1.71% $0.02 398.20%
State Street Corp 1.78M Mar 31, 2025 1.68% $0.01 -4.99%
Weiss Asset Management LP 1.64M Mar 31, 2025 1.54% $4.36 0.00%
Glazer Capital, LLC 1.58M Mar 31, 2025 1.49% $9.64 0.00%
Goldman Sachs Group Inc 1.47M Mar 31, 2025 1.39% $0.03 291.52%
Morgan Stanley - Brokerage Accounts 1.40M Mar 31, 2025 1.32% $0.01 57.26%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.09M Mar 31, 2025 1.03% $0.53 0.00%
Test Hedge Fund Mgmt 1.06M Mar 31, 2025 0.99% $8.73 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 BB Biotech AG Ord 2.43M 2.28% ▼ 1.82% Dec 31, 2024
2 Fidelity Contrafund 1.20M 1.13% ▲ 0.00% Mar 31, 2025
3 BSF Global Event Driven Z2 USD 612.87K 0.58% ▲ 0.00% Mar 31, 2025
4 Fidelity Extended Market Index 547.31K 0.51% ▲ 1.86% Mar 31, 2025
5 Fidelity Contrafund Commingled Pl S 524.39K 0.49% ▲ 0.33% Mar 31, 2025
6 Fidelity Mid Cap Index 340.36K 0.32% ▲ 2.69% Mar 31, 2025
7 Blackrock Russ 1000 Eq Idx Composite 339.67K 0.32% ▲ 8.42% Mar 31, 2025
8 Picton Mahoney Fortified Arbtrg Pl Alt F 294.70K 0.28% ▲ 33.53% Mar 31, 2025
9 UBS: US Equity Small Cap Growth 281.52K 0.26% ▲ 0.00% Sep 30, 2024
10 Fidelity Contrafund K6 272.61K 0.26% ▼ 0.63% Mar 31, 2025

Financial Highlights

▼
Market Cap: $14.05B
EBITDA: $-116.21M
PEG Ratio: $0.00
Book Value: $10.81
Earnings/Share: $-0.73
Profit Margin: -10.97%
Operating Margin: -14.66%
ROA (TTM): -6.96%
ROE (TTM): -8.58%
Revenue (TTM): $680.85M
Revenue/Share (TTM): $6.60
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 50.80%

Valuation Metrics

Enterprise Value: $13.06B
Trailing P/E: 0.00
Forward P/E: 158.73

Shares Statistics

Shares Outstanding: 106.52M
Shares Float: 104.82M
% Insiders: 2.48%
% Institutions: 96.45%
Shares Short: 2.67M
Shares Short (Prior Month): 2.33M
Short Ratio: 1.20
Short % Float: 2.54%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$680.85M
Cost of Goods Sold
adjust
$-56.96M
Gross Profit
subtotal
$623.89M
SG&A
adjust
$-504.49M
R&D
adjust
$-236.12M
Operating Income
subtotal
$-116.72M
Other / Non-Operating Items
adjust
$42.05M
Net Income
subtotal
$-74.68M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ITCI.US!